175 related articles for article (PubMed ID: 35896912)
1. Recent topics of the clinical utility of PET/MRI in oncology and neuroscience.
Nakamoto Y; Kitajima K; Toriihara A; Nakajo M; Hirata K
Ann Nucl Med; 2022 Sep; 36(9):798-803. PubMed ID: 35896912
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [
Mirshahvalad SA; Eisazadeh R; Shahbazi-Akbari M; Pirich C; Beheshti M
Semin Nucl Med; 2024 Jan; 54(1):171-180. PubMed ID: 37752032
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Ferraro DA; Burger IA
Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
6. Artificial Intelligence in Breast Cancer: A Systematic Review on PET Imaging Clinical Applications.
Alongi P; Rovera G; Stracuzzi F; Popescu CE; Minutoli F; Arnone G; Baldari S; Deandreis D; Caobelli F
Curr Med Imaging; 2023; 19(8):832-843. PubMed ID: 36703586
[TBL] [Abstract][Full Text] [Related]
7.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
8. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
11. Breast PET/MRI Hybrid Imaging and Targeted Tracers.
Romeo V; Helbich TH; Pinker K
J Magn Reson Imaging; 2023 Feb; 57(2):370-386. PubMed ID: 36165348
[TBL] [Abstract][Full Text] [Related]
12.
Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
[TBL] [Abstract][Full Text] [Related]
13. [PET-CT and PET-MRI of the prostate : From
Knorr K; Eiber M; Maurer T; Wester HJ; Scheidhauer K
Radiologe; 2017 Aug; 57(8):631-636. PubMed ID: 28688023
[TBL] [Abstract][Full Text] [Related]
14. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A
Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268
[TBL] [Abstract][Full Text] [Related]
15. MRI fused with prone FDG PET/CT improves the primary tumour staging of patients with breast cancer.
Garcia-Velloso MJ; Ribelles MJ; Rodriguez M; Fernandez-Montero A; Sancho L; Prieto E; Santisteban M; Rodriguez-Spiteri N; Idoate MA; Martinez-Regueira F; Elizalde A; Pina LJ
Eur Radiol; 2017 Aug; 27(8):3190-3198. PubMed ID: 28004161
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.
Ohno Y; Kishida Y; Seki S; Koyama H; Yui M; Aoyagi K; Yoshikawa T
Acad Radiol; 2022 Mar; 29 Suppl 3():S122-S131. PubMed ID: 29395795
[TBL] [Abstract][Full Text] [Related]
17. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.
Joshi A; Roberts MJ; Perera M; Williams E; Rhee H; Pryor D; Lehman M; Heathcote P; Wood S; Coucher J; Gustafson S; Miles K; Vela I
Clin Exp Metastasis; 2020 Aug; 37(4):551-560. PubMed ID: 32519046
[TBL] [Abstract][Full Text] [Related]
18. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
Lin CY; Lin CL; Kao CH
Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
[TBL] [Abstract][Full Text] [Related]
19. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
McEwan LM; Wong D; Yaxley J
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
[TBL] [Abstract][Full Text] [Related]
20.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
